Valeant Pharmaceuticals VRX
The three reasons
- 1
Philidor and R&O Pharmacy are the same entity — evidence of phantom accounts to book revenue
- 2
Valeant built a network of captive clone pharmacies (Orbit, West Wilshire, Safe Rx) to stuff the channel
- 3
Pattern mirrors Enron: McKinsey-bred CEO, undisclosed consolidation, rhetoric of being misunderstood
Primary demands
- Investors should treat Valeant as a potential fraud and exit the stock
- Auditors and regulators should investigate undisclosed Philidor relationship and captive pharmacy network
- Board audit committee (chaired by Norma Provencio) should be held accountable for non-disclosure
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notable slides (6)
Notes
Landmark Citron short report that catalyzed Valeant's collapse. Not a slide deck — a text-heavy research note with embedded evidence screenshots (Valeant's own investor slide about R&O, matched privacy-notice PDFs proving Philidor and R&O share management, same toll-free privacy officer number across clone pharmacies). Core rhetorical moves: (1) 'Smoking Gun' SCQA framing anchored on identical website boilerplate, (2) side-by-side Enron/Valeant CEO quote table, (3) Skilling-vs-Pearson bio parallel (both ex-McKinsey, 0 yrs operating experience), (4) Arthrocare/Discocare historical analog with 'CEO now doing 20 years' kicker. Closes with Galileo epigraph and 'Extremely Cautious Investing to All' sign-off. Villain-naming extends beyond CEO to audit committee chair, citing prior Bronte Capital post on Signalife/Mitchell Stein association. Peer-comparison present but historical (vs. Enron/Arthrocare fraud cases) rather than operating peers — no peer-gap chart in the conventional sense.